Bosentan for digital ulcers in patients with systemic sclerosis: A prospective 3-year followup study

Journal of Rheumatology

Volumn 36, Issue 7, 2009, Pages 1550-1551

  Tsifetaki, Niki ^a   Botzoris, Vassilios ^c   Alamanos, Yannis ^b   Argyriou, Evaggelia ^c   Zioga, Aikaterini ^a   Drosos, Alexandros A ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; DIGITAL ULCER; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEMATOCRIT; HUMAN; HUMAN TISSUE; LETTER; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; SKIN ULCER; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME; WOUND HEALING;

AGED; ANTIHYPERTENSIVE AGENTS; BIOPSY; FEMALE; FINGERS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC; SKIN; SKIN ULCER; SULFONAMIDES; TREATMENT OUTCOME;

EID: 67650505639     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.080992     Document Type: Letter

References (10)

1. Charles C, Clements P, Furst DE. Systemic sclerosis: hypothesis-driven treatment strategies. Lancet 2006;367:1683-91.
2. Denton C, Korn J. Digital ulceration and critical digital ischemia in scleroderma. Scleroderma Care Res 2003;1:12-6.
3. Roux S, Breu V, Ertel SI, Clozel M. Endothelin antagonism with bosentan: a review of potential applications. J Mol Med 1999;77:364-76.
4. Rubin LJ, Badesch DB. Evaluation and management of the patient with pulmonary arterial hypertension. Ann Intern Med 2005;143:282-92.
5. Korn JH, Mayes M, Matucci Cerinic M, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004;50:3985-93.
6. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
7. Chung L, Fiorentino D. Digital ulcers in patients with systemic sclerosis. Autoimmun Rev 2006;5:125-8.
8. Abou Raya A, Abou-Raya S, Helmii M. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers. J Rheumatol 2008;35:1801-8.
9. Kawald A, Burmester GR, Huscher D, Sunderkotter C, Riemekasten G. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study. J Rheumatol 2008;35:1830-7.
10. García de la Peña-Lefebvre P, Rodríguez Rubio S, Valero Expósito M, et al. Long-term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients. Rheumatology 2008;47:464-6.